Clinical trials: Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab)…
- Trial name
- CaDAnCe-303 (NCT06970743)
- Testing
- BGB-16673, Bendamustine, Rituximab
- Where
- 56 sites in China, Taiwan
- Volunteers
- 153 people
- Sponsor
- BeOne Medicines
Leukemia, Lymphoma
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00026351
- Testing
- rituximab, pentostatin
- Where
- 5 sites in United States
- Sponsor
- Pharmatech Oncology
Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological tumor.
- Conditions
- Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT04279405
- Testing
- YY-20394
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT07218341
- Testing
- Pirtobrutinib, Idelalisib
- Where
- 50 sites in United States, Australia and 15 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a…
- Trial name
- NCT07221500
- Testing
- NX-5948
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Nurix Therapeutics, Inc.
CLL/SLL
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
- Trial name
- NCT06319456
- Testing
- Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine
- Where
- 10 sites in China
- Volunteers
- 344 people
- Sponsor
- Ascentage Pharma Group Inc.
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT07520006
- Testing
- NX-5948, venetoclax, rituximab
- Where
- 6 sites in United States
- Volunteers
- 150 people
- Sponsor
- Nurix Therapeutics, Inc.
Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
This is a Phase I/II, single-arm, multicenter, open-label study which is divided into two portions: Phase I is dose escalation portion, in which subjects with relapsed or refractory B-cell lymphoma will be enrolled except…
- Conditions
- Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
- Trial name
- NCT05720052
- Testing
- MS-553
- Where
- China
- Volunteers
- 8 people
- Sponsor
- MingSight Pharmaceuticals, Inc
Hematologic Neoplasms
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.
This study will determine the maximum tolerated dose of RO5045337 and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with hematologic neoplasms.
- Trial name
- NCT00623870
- Testing
- RO5045337
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Lymphoid, Lymphoma, Non-Hodgkin
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
- Conditions
- Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT04849416
- Testing
- LOXO-305
- Where
- 22 sites in China
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Secondary Immune Deficiency
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor…
- Trial name
- NCT07648264
- Testing
- IgPro20
- Where
- 60 sites in United States, Belgium and 9 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), Marginal Zone B Cell Lymphoma
- Trial name
- NCT02914938
- Testing
- ME-401, Rituximab, Zanubrutinib
- Where
- 24 sites in United States, Switzerland
- Volunteers
- 97 people
- Sponsor
- MEI Pharma, Inc.
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the effect of the addition of idelalisib to rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Yosemite (NCT01732913)
- Testing
- Rituximab, Idelalisib
- Where
- 103 sites in United States, Australia and 17 more
- Volunteers
- 295 people
- Sponsor
- Gilead Sciences
Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia
A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
To Evaluate the Efficacy and Safety of TQB3909 Tablets versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Trial name
- NCT07753369
- Testing
- TQB3909 Tablets, Bendamustine Injection, Rituximab injection
- Where
- 2 sites in China
- Volunteers
- 128 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hematologic Cancer
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of…
- Trial name
- NCT05753501
- Testing
- ABBV-101, Venetoclax
- Where
- 51 sites in United States, Canada and 7 more
- Volunteers
- 135 people
- Sponsor
- AbbVie
Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion
A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion
- Trial name
- NCT01744691
- Testing
- Ibrutinib
- Where
- 55 sites in United States, Australia and 7 more
- Volunteers
- 145 people
- Sponsor
- Pharmacyclics LLC.
Relapsed or Refractory Chronic Lymphocytic Leukemia
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT03739554
- Testing
- CYC065, Venetoclax
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Leukemia, Lymphoma
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Biological therapies such as denileukin diftitox may be able to deliver cancer-killing substances directly to non-Hodgkin's lymphoma cells.
- Trial name
- NCT00026429
- Testing
- denileukin diftitox
- Where
- 6 sites in United States
- Sponsor
- Pharmatech Oncology
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
This study is designed to determine the recommended phase 2 dose (RP2D), and the safety, and efficacy of durvalumab as monotherapy and when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and…
- Trial name
- FUSION NHL 001 (NCT02733042)
- Testing
- Durvalumab, Lenalidomide, Rituximab
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 106 people
- Sponsor
- Celgene
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL)
- Trial name
- NCT04830137
- Testing
- NX-2127
- Where
- 16 sites in United States
- Volunteers
- 248 people
- Sponsor
- Nurix Therapeutics, Inc.